secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008469
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties
--------------------------------------------------------------------------------

- Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.
- Total revenue of $18.7M, down 7% YoY, all royalty from AbbVie's HCV regimen MAVYRET.
- Cash and securities $322.5M; expects to fund operations for at least two years.
- Expects topline data from RSVP Phase 2b study of EDP-938 in adults with RSV this quarter.
- FDA Fast Track for EDP-235 (COVID-19); preliminary Phase 1 data expected this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/0000950170-22-008469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017022008469/enta-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer